TrialCompass TCL
Find TrialsAI AssistantLetter GeneratorAbout
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT07278856

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is evaluating Biospecimen Collection, Bone Marrow Aspiration, and other medications as a treatment for people newly diagnosed with a type of T-cell lymphoma called AITL. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Bone Marrow Aspiration (PROCEDURE): Undergo bone marrow biopsy and aspiration | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy and aspiration | Computed Tomography (PROCEDURE): Undergo CT and FDG-PET/CT | Cyclophosphamide (DRUG): Given IV | Doxorubicin (DRUG): Given IV | Echocardiography Test (PROCEDURE): Undergo ECHO | FDG-Positron Emission Tomography (PROCEDURE): Undergo FDG-PET/CT | Filgrastim (BIOLOGICAL): Given SC | Fludeoxyglucose F-18 (OTHER): Given FDG | Multigated Acquisition Scan (PROCEDURE): Undergo MUGA | Pegfilgrastim (BIOLOGICAL): Given SC | Prednisone (DRUG): Given PO | Questionnaire Administration (OTHER): Ancillary studies | Ruxolitinib Phosphate (DRUG): Given PO | Vincristine (DRUG): Given IV

Drugs / treatments
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Filgrastim, Fludeoxyglucose F-18, Multigated Acquisition Scan, Pegfilgrastim, Prednisone, Questionnaire Administration, Ruxolitinib Phosphate, Vincristine
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

At a glance

Phase
Phase 1
Status
Recruiting
Design
Non-randomized, open-label
Enrollment target
20 patients
Primary endpoint
Maximum tolerated dose (MTD) of ruxolitinib when given in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy; Incidence of adverse events
Ages
18 Years to —
Start date
2025-12-16
Est. completion
2027-03-31

Locations

1 US sites · 1 total

California

Contact

Sponsor
City of Hope Medical Center (OTHER)
Contact
—

Tags

AITL/TFHPTCL-NOSNewly diagnosed
TrialCompass — Clinical Trial Summary

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

NCT07278856

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is evaluating Biospecimen Collection, Bone Marrow Aspiration, and other medications as a treatment for people newly diagnosed with a type of T-cell lymphoma called AITL. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Bone Marrow Aspiration (PROCEDURE): Undergo bone marrow biopsy and aspiration | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy and aspiration | Computed Tomography (PROCEDURE): Undergo CT and FDG-PET/CT | Cyclophosphamide (DRUG): Given IV | Doxorubicin (DRUG): Given IV | Echocardiography Test (PROCEDURE): Undergo ECHO | FDG-Positron Emission Tomography (PROCEDURE): Undergo FDG-PET/CT | Filgrastim (BIOLOGICAL): Given SC | Fludeoxyglucose F-18 (OTHER): Given FDG | Multigated Acquisition Scan (PROCEDURE): Undergo MUGA | Pegfilgrastim (BIOLOGICAL): Given SC | Prednisone (DRUG): Given PO | Questionnaire Administration (OTHER): Ancillary studies | Ruxolitinib Phosphate (DRUG): Given PO | Vincristine (DRUG): Given IV

Drugs / treatments: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Filgrastim, Fludeoxyglucose F-18, Multigated Acquisition Scan, Pegfilgrastim, Prednisone, Questionnaire Administration, Ruxolitinib Phosphate, Vincristine

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 20 patients

Primary endpoint: Maximum tolerated dose (MTD) of ruxolitinib when given in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy; Incidence of adverse events

Ages: 18 Years to —

Start date: 2025-12-16 | Est. completion: 2027-03-31

Locations

1 US sites · 1 total

California

Contact

—

Sponsor: City of Hope Medical Center (OTHER)

Tags

AITL/TFH · PTCL-NOS · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07278856

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.
TrialCompass

A free tool to help patients, caregivers, and clinicians find and understand clinical trials for T-cell lymphoma.

Explore

  • Find Trials
  • AI Assistant
  • Letter Generator
  • About
  • Share Your Feedback
  • Terms of Use
  • Privacy Policy

Data sourced from ClinicalTrials.gov.

For informational purposes only. Not medical advice — always consult your healthcare team.

Built with care for the rare cancer community.

Data last updated: June 2026

Edit with